Dr Chen Kaina

Dr Chen Kaina is an accredited specialist in the field of Gastroenterology & Hepatology. She obtained her specialist accreditation in Gastroenterology and holds a Master of Clinical Investigation from the National University of Singapore.
She manages a wide range of gastrointestinal conditions including disorders of the oesophagus, stomach, and intestines, and has a clinical interest in hepatology, including liver cirrhosis, viral hepatitis, metabolic liver disease, portal hypertension and liver cancer as part of the multi-disciplinary management.

Dr Chen is actively engaged in clinical and translational research, with a focus on liver cancer and early detection in Asian populations. She has received competitive research funding, including SingHealth Pitch-for-Fund and National Medical Research Council (NMRC) seed grants.
She is a regular speaker at local and international conferences and is actively involved in medical education. She holds an academic appointment as Clinical Assistant Professor at Duke-NUS Medical School.

• Fellow, Academy of Medicine, Singapore
• Member, Royal College of Medicine, UK (London)
• Member, American Association for the Study of Liver Disease (AASLD)
• Member, European Association for the Study of Liver Disease (EASL)

• Service with a Heart Award, Singapore General Hospital
• Best Presentation Award, Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)
• QI Project Award (Improving Bowel Preparations), Singapore General Hospital, 2019

• Chen K., Sng WK., Quah JHM et al., Clinical Spectrum of Non-Alcoholic Fatty Liver Disease in patients with Diabetes Mellitus. Plos One; 2020 15(8):e0236977.
• Chen K., Chang PE., Goh GBB., Tan CK. Surveillance for hepatocellular carcinoma – current status and advances. Hepatoma Research 2018; 4:72
• Chen, K., Shuen, T.W.H. & Chow, P.K.H. The association between tumour heterogeneity and immune evasion mechanisms in hepatocellular carcinoma and its clinical implications. Br J Cancer 131, 420–429 (2024).
• Chen K., Aaron K.T. Tong et al., The impact of radiation dose and tumour burden on outcomes in hepatocellular carcinoma: 11-year experience in a 413-patient cohort treated with yttrium-90 resin microsphere radioembolisation. Liver Cancer 2024;
• Lin HY, Jeon AJ, Chen K, Lee CJM, Wu L, Chong SL, Anene-Nzelu CG, Foo RS, Chow PK. The epigenetic basis of hepatocellular carcinoma - mechanisms and potential directions for biomarkers and therapeutics. Br J Cancer. 2025 Mar 8.
• Fong J., Chen K., Goh CXY., Huang HL., Loke KSH., Tong AKT. Clinical impact of Y-90 resin microsphere radioembolization-induced hepatic adverse events and associations with predictive dosimetry; Nucl Med Commun 2026 Feb 1;47(2):177-184.
• Liou, W.-L., Tan, T.J.-Y., Chen, K., et al., Gender survival differences in hepatocellular carcinoma: Is it all due to adherence to surveillance? A study of 1716 patients over three decades. JGH Open, 2023, 7: 377-386.
• Seshachalam, Veerabrahma P….. Chen K.,….. et al. Multiomics and multi-region spatial transcriptome analysis reveal cellular networks and pathways associated with HCC recurrence; JHEP Reports, 2026